Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes

Schneider, A., Schneider, M.P., Scharnagl, H., Jardine, A.G. , Wanner, C. and Drechsler, C. (2013) Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes. BMC Nephrology, 14(67), (doi: 10.1186/1471-2369-14-67)

[img]
Preview
Text
79131.pdf - Published Version
Available under License Creative Commons Attribution.

209kB

Abstract

<p>Background: Resistance to ESAs (erythropoietin stimulating agents) is highly prevalent in hemodialysis patients with diabetes and associated with an increased mortality. The aim of this study was to identify predictors for ESA resistance and to develop a prediction model for the risk stratification in these patients.</p> <p>Methods: A post-hoc analysis was conducted of the 4D study, including 1015 patients with type 2 diabetes undergoing hemodialysis. Determinants of ESA resistance were identified by univariate logistic regression analyses. Subsequently, multivariate models were performed with stepwise inclusion of significant predictors from clinical parameters, routine laboratory and specific biomarkers.</p> <p>Results: In the model restricted to clinical parameters, male sex, shorter dialysis vintage, lower BMI, history of CHF, use of ACE-inhibitors and a higher heart rate were identified as independent predictors of ESA resistance. In regard to routine laboratory markers, lower albumin, lower iron saturation, higher creatinine and higher potassium levels were independently associated with ESA resistance. With respect to specific biomarkers, higher ADMA and CRP levels as well as lower Osteocalcin levels were predictors of ESA resistance.</p> <p>Conclusions: Easily obtainable clinical parameters and routine laboratory parameters can predict ESA resistance in diabetic hemodialysis patients with good discrimination. Specific biomarkers did not meaningfully further improve the risk prediction of ESA resistance. Routinely assessed data can be used in clinical practice to stratify patients according to the risk of ESA resistance, which may help to assign appropriate treatment strategies.</p>

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Schneider, Dr Markus and Schneider, Dr Andreas and Jardine, Professor Alan
Authors: Schneider, A., Schneider, M.P., Scharnagl, H., Jardine, A.G., Wanner, C., and Drechsler, C.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:BMC Nephrology
Publisher:BioMed Central
ISSN:1471-2369
Copyright Holders:Copyright © 2013 The Authors
First Published:First published in BMC Nephrology 14:67
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record